Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it...

Related Keywords

United States ,Germany ,Peter Maag ,Christian Pflaumer ,Kyverna Therapeutics Inc ,Drug Administration ,National Institutes Of Health ,Track Designation ,Patients With Refractory Myasthenia ,Kyverna Therapeutics ,National Institutes ,Media Contact ,Nature Medicine ,